Stock Chart
VTRS
This target is derived from long-term trendline analysis and projected growth.
Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.
Target may adjust dynamically as the stock trend reverses or accelerates.
Type: SELL wallstreet
Strike: $12
Premium: $2.25
Expiry: Jan 15, 2027
Target: $13
Score: -51
LEAPs are long-term options (1+ year) with less time decay.
This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.
How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future
Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling
⚠️ Not a prediction. Shows trend projection only.
R-squared: 0.87
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About VTRS - Viatris Inc. Common Stock
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy …
Key Statistics
More VTRS Analysis
This VTRS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track VTRS's price movements with trendlines, gamma walls, and key support/resistance levels.